SlideShare a Scribd company logo
Measles
Measles or RubeolA, is an acute viral illness
caused by a virus in the family paramyxovirus,
genus Morbillivirus.
Measles is characterized by a prodrome of fever and
malaise, cough, coryza, and conjunctivitis, followed by a
maculopapular rash.
Measles is usually a mild or moderately severe
illness. However, measles can result in
complications such as pneumonia,
encephalitis and death.
Epidemiology
• In 1980, before widespread global use of measles
  vaccine, an estimated 2.6 million measles deaths
  occurred worldwide. In 2001, to accelerate the
  reduction in measles cases achieved by vaccination,
  the World Health Organization (WHO) and the United
  Nations Children's Fund (UNICEF) developed a strategy
  to deliver 2 doses of measles-containing vaccine (MCV)
  to all children through routine services and
  supplementary immunization activities (SIAs) and
  improved disease surveillance. After implementation of
  this strategy, the estimated number of annual measles
  deaths worldwide decreased from 733,000 in 2000 to
  164,000 in 2008.
Transmission
Measles transmission is airborne by
respiratory droplet nuclei spread or it can be
transmitted by direct contact with infected
nasal or throat secretions.
Incubation Period
The incubation period is approximately ten
days, but varies from 7 to 18 days from
exposure to the onset of fever. It is usually 14
days until the rash appears.
Risk Factors
Anyone who never had measles and has never
been vaccinated.
Babies younger than 12 months old, because they
are too young to be vaccinated.
Adults who were vaccinated before 1968,
because some early vaccines did not give lasting
protection.
A very small percentage of vaccinated children
and adults who may not have responded well to
the vaccine.
Clinical Features
• Clinical features of measles include prodromal
  fever, a severe cough, conjunctivitis, coryza
  and Koplik’s spots on the buccal mucosa.
  These are present for three to four days prior
  to rash onset.
The most important clinical predictors are included in the
  clinical case definition for measles which is an illness
  characterised by all the following features:
 generalised maculopapular rash, usually lasting three or more
  days
 fever (at least 38°C if measured) present at the time of rash
  onset
 cough, coryza, conjunctivitis and Koplik’s spots
 The characteristic red, blotchy rash appears on the third to
  seventh day. It begins on the face before becoming
  generalised and generally lasts four to seven days.
 Measles infection (confirmed virologically) may rarely occur
  without a rash.
ASSESSMENT
PROBLEM IDENTIFIED
                   STAGE                                 DATA                                   (NURSING DIAGNOSIS)

Pre-eruptive Stage                    •   fever                                      •   Hyperthermia

(patient is highly communicable)      •   catarrhal symptoms – start in the nasal    •   Pain
                                          cavities; then in the conjunctivae,        •   Risk for impaired gas exchange
                                          oropharynx, progress to the bronchi        •   Risk for impaired breathing pattern
                                          resulting successively in rhinitis,
                                          conjunctivitis and then bronchitis.
                                      •   Respiratory symptoms – which appear
                                          first as a common cold, and sneezing
                                          nasal discharges, steadily progress into
                                          a distressing and annoying cough that
                                          persists up to convalescence.

Eruptive Stage/Stage of Skin Rashes   •   Anorexia                                   •   Imbalance nutrition: less than body
                                                                                         requirement
                                      •   Exanthem sign – means eruption in the
                                          skin                                       •   Impaired skin integrity

                                      •   Maculopapular Rashes – appears 2-7         •   Hyperthermia
                                          days after onset                           •   Activity Intolerance
                                      •   High fever – increases steadily            •   Fatigue
                                      •   Irritability
                                      •   Diarrhea
                                      •   Pruritis
                                      •   Lethargy
                                      •   Occipital lymphadenopathy

Stage of Convalescence                •   Rashes – fade in the same manner as
                                          they appeared, from the face
                                          downwards, leaving a dirty brown
                                          pigmentation and finely granular which
                                          maybe noted for several days.
                                      •   Fever – gradually subsides as the
                                          eruptions disappear on the hands and
                                          feet
DIAGNOSIS
Clinical diagnosis of measles requires a history
of fever of at least three days, with at least
one of the three C's (cough, coryza,
conjunctivitis). Observation of Koplik's spots is
also diagnostic of measles.
Alternatively, laboratory diagnosis of measles can
be done with confirmation of positive measles
IgM antibodies or isolation of measles virus RNA
from respiratory specimens. In patients where
phlebotomy is not possible, saliva can be
collected for salivary measles-specific IgA testing.
Positive contact with other patients known to
have measles adds strong epidemiological
evidence to the diagnosis. The contact with any
infected person in any way, including semen
through sex, saliva, or mucus, can cause infection.
MANAGEMENT
•   There is no specific treatment for measles. Most patients with uncomplicated
    measles will recover with rest and supportive treatment. It is, however, important
    to seek medical advice if the patient becomes more unwell, as they may be
    developing complications. Patient should be monitored for the development of
    bacterial infections which should be treated with appropriate antibiotics on the
    basis of clinical and bacteriological finding

•   The patient may also take over-the-counter medications such as acetaminophen
    (Tylenol, others) or nonsteroidal anti-inflammatory drugs (NSAIDs) to help relieve
    the fever that accompanies measles. Don’t give aspirin to children because of the
    risk of Reye’s syndrome — a rare but potentially fatal disease.

•   Maintain bedrest and provide quiet activities for the child. If there is sensitivity to
    light, keep room darkly lit. Remove eye secretions with warm saline or water.
    Encourage the patient not to rub the eyes. Administer antipyretic medication and
    tepid sponge baths as ordered. A cool mist vaporizer can be used to relieve cough.
    Apply antipruritic medication to prevent itching. Isolate child until fifth day of rash.
Prevention of Measles

• Avoid exposing children to any person with fever or with acute
  catarrhal symptoms
• Isolation of cases from diagnosis until about 5-7 days after onset of
  rash
• Disinfection of all articles soiled with secretion of nose and throat
• Encourage by health department and by private physician of
  administration of measles immune globulin to susceptible infants
  and children under 3 years of age in families or institutions where
  measles occurs.
• Live attenuated and inactivated measles virus vaccines have been
  tested and are available for use in children with no history of
  measles, at 9 months of age or soon thereafter
• Live attenuated measles vaccine is recommended for
  all persons unless specific contra-indications to live
  vaccines exist.

• It is recommended that this vaccine be given as
  measles-mumps-rubella (MMR) vaccine at 9 to 12
  months of age and a second dose at four years of age
  (prior to school entry). The second dose is not a
  booster but is designed to vaccinate the approximately
  five per cent of children who do not seroconvert to
  measles after the first dose of vaccine
GUIDE ON MEASLES IMMUNIZATION

Route                 Subcutaneous
Site                  Outer part of upper left arm
Number of Dose        1 dose
Age at First Dose     9 months
Dosage                0.5mL
Storage Temperature   -15 to -25 °C
EVALUATION
• PROGNOSIS

  While the vast majority of patients survive measles, complications
  occur fairly frequently, and may include bronchitis,
  and panencephalitis which is potentially fatal. Also, even if the
  patient is not concerned about death or sequela from the measles,
  the person may spread the disease to an immunocompromised
  patient, for whom the risk of death is much higher, due to
  complications such as giant cell pneumonia. Acute measles
  encephalitis is another serious risk of measles virus infection. It
  typically occurs two days to one week after the breakout of the
  measles exanthem, and begins with very high fever, severe
  headache, convulsions, and altered mentation. Patient may become
  comatose, and death or brain injury may occur.
Measles

More Related Content

What's hot

Rubella (German Measles)
Rubella (German Measles)Rubella (German Measles)
Rubella (German Measles)
KULDEEP VYAS
 
Measles.pptx
Measles.pptxMeasles.pptx
Measles.pptx
ABHIJIT BHOYAR
 
Diphtheria
DiphtheriaDiphtheria
Diphtheria
KULDEEP VYAS
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
Sameh Abdel-ghany
 
Typhoid disease
Typhoid diseaseTyphoid disease
Typhoid disease
WahidahPuteriAbah
 
Chicken pox
Chicken poxChicken pox
Chicken pox
Nidhi Chauhan
 
Diphteria
DiphteriaDiphteria
Diphteria
Gugsa Germossa
 
Chicken pox
Chicken poxChicken pox
Chicken pox
Ashok Jaisingani
 
Pharyngitis
PharyngitisPharyngitis
Pharyngitis
Manikandan T
 
Malaria
MalariaMalaria
EPIDEMIOLOGY OF CHICKEN POX
EPIDEMIOLOGY OF CHICKEN POXEPIDEMIOLOGY OF CHICKEN POX
EPIDEMIOLOGY OF CHICKEN POX
MAHESWARI JAIKUMAR
 
Chikungunya fever
Chikungunya feverChikungunya fever
Chikungunya fever
Arifa T N
 
Measles
Measles Measles
Meningococcal meningitis dr.harivansh chopra
Meningococcal meningitis dr.harivansh chopraMeningococcal meningitis dr.harivansh chopra
Meningococcal meningitis dr.harivansh chopra
Harivansh Chopra
 
Mumps
MumpsMumps
BCG vaccine
BCG vaccineBCG vaccine
BCG vaccine
Ali Najat
 
Typhoid fever ppt.
Typhoid fever ppt.Typhoid fever ppt.
Typhoid fever ppt.
sapanathakor
 

What's hot (20)

Rubella (German Measles)
Rubella (German Measles)Rubella (German Measles)
Rubella (German Measles)
 
Measles.pptx
Measles.pptxMeasles.pptx
Measles.pptx
 
Diphtheria
DiphtheriaDiphtheria
Diphtheria
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
 
Typhoid disease
Typhoid diseaseTyphoid disease
Typhoid disease
 
Chicken pox
Chicken poxChicken pox
Chicken pox
 
Diphteria
DiphteriaDiphteria
Diphteria
 
Mumps
Mumps Mumps
Mumps
 
Smallpox disease
Smallpox diseaseSmallpox disease
Smallpox disease
 
Chicken pox
Chicken poxChicken pox
Chicken pox
 
Pharyngitis
PharyngitisPharyngitis
Pharyngitis
 
Malaria
MalariaMalaria
Malaria
 
EPIDEMIOLOGY OF CHICKEN POX
EPIDEMIOLOGY OF CHICKEN POXEPIDEMIOLOGY OF CHICKEN POX
EPIDEMIOLOGY OF CHICKEN POX
 
Chikungunya fever
Chikungunya feverChikungunya fever
Chikungunya fever
 
Measles
Measles Measles
Measles
 
Meningococcal meningitis dr.harivansh chopra
Meningococcal meningitis dr.harivansh chopraMeningococcal meningitis dr.harivansh chopra
Meningococcal meningitis dr.harivansh chopra
 
Mumps
MumpsMumps
Mumps
 
BCG vaccine
BCG vaccineBCG vaccine
BCG vaccine
 
Typhoid fever ppt.
Typhoid fever ppt.Typhoid fever ppt.
Typhoid fever ppt.
 
Mumps presentation s agun
Mumps presentation   s agunMumps presentation   s agun
Mumps presentation s agun
 

Similar to Measles

Measles and rubella
Measles and rubellaMeasles and rubella
Measles and rubella
Khagendra Shrestha
 
vaccine pre1.pptx
vaccine pre1.pptxvaccine pre1.pptx
vaccine pre1.pptx
WoinshetMelaku
 
Measles .pptx
Measles .pptxMeasles .pptx
Measles .pptx
Beema3
 
Measles .pptx
Measles .pptxMeasles .pptx
Measles .pptx
Beema3
 
24. mumps, measels, rubella
24. mumps, measels, rubella24. mumps, measels, rubella
24. mumps, measels, rubella
Ratheeshkrishnakripa
 
Infectious diseases in children
Infectious diseases in childrenInfectious diseases in children
Infectious diseases in children
Azad Haleem
 
Fever with a maculopapular skin rash in children 2021
Fever with a maculopapular skin rash in children 2021Fever with a maculopapular skin rash in children 2021
Fever with a maculopapular skin rash in children 2021
Imran Iqbal
 
COmmon childhood exanthems by Jason Enukora.pptx
COmmon childhood exanthems by Jason Enukora.pptxCOmmon childhood exanthems by Jason Enukora.pptx
COmmon childhood exanthems by Jason Enukora.pptx
jasonenukora1998
 
Fever and rash by Dr.Uma
Fever and rash by Dr.UmaFever and rash by Dr.Uma
Fever and rash by Dr.UmaDr. Rubz
 
Common Viral Infections in children.pptx
Common Viral Infections in children.pptxCommon Viral Infections in children.pptx
Common Viral Infections in children.pptx
Gayathri Nair
 
11 Measles
11 Measles11 Measles
11 Measlesghalan
 
Mumps & Rubella.pptx
Mumps & Rubella.pptxMumps & Rubella.pptx
Mumps & Rubella.pptx
Rahul Netragaonkar
 
MEASLES, COMPLICATIONS AND POST DEBILITY.pptx
MEASLES, COMPLICATIONS AND POST DEBILITY.pptxMEASLES, COMPLICATIONS AND POST DEBILITY.pptx
MEASLES, COMPLICATIONS AND POST DEBILITY.pptx
ValentinaEmeruwa
 
Measles
MeaslesMeasles
Measles
zaidbintariq2
 
Common commin child hood
Common commin child hoodCommon commin child hood
Common commin child hood
ann geo
 
Measles
MeaslesMeasles
epidemiology of common infectious diseases-resp,git,arthropod.pptx
epidemiology of common infectious diseases-resp,git,arthropod.pptxepidemiology of common infectious diseases-resp,git,arthropod.pptx
epidemiology of common infectious diseases-resp,git,arthropod.pptx
sanakhader3
 
Common Pediatric Viral Exanthems
Common Pediatric Viral Exanthems Common Pediatric Viral Exanthems
Common Pediatric Viral Exanthems
Fatima Farid
 
measles.pdf
measles.pdfmeasles.pdf
measles.pdf
AnushriSrivastav
 

Similar to Measles (20)

Measles and rubella
Measles and rubellaMeasles and rubella
Measles and rubella
 
vaccine pre1.pptx
vaccine pre1.pptxvaccine pre1.pptx
vaccine pre1.pptx
 
Measles .pptx
Measles .pptxMeasles .pptx
Measles .pptx
 
Measles .pptx
Measles .pptxMeasles .pptx
Measles .pptx
 
24. mumps, measels, rubella
24. mumps, measels, rubella24. mumps, measels, rubella
24. mumps, measels, rubella
 
Infectious diseases in children
Infectious diseases in childrenInfectious diseases in children
Infectious diseases in children
 
Fever with a maculopapular skin rash in children 2021
Fever with a maculopapular skin rash in children 2021Fever with a maculopapular skin rash in children 2021
Fever with a maculopapular skin rash in children 2021
 
COmmon childhood exanthems by Jason Enukora.pptx
COmmon childhood exanthems by Jason Enukora.pptxCOmmon childhood exanthems by Jason Enukora.pptx
COmmon childhood exanthems by Jason Enukora.pptx
 
Fever and rash by Dr.Uma
Fever and rash by Dr.UmaFever and rash by Dr.Uma
Fever and rash by Dr.Uma
 
Common Viral Infections in children.pptx
Common Viral Infections in children.pptxCommon Viral Infections in children.pptx
Common Viral Infections in children.pptx
 
11 Measles
11 Measles11 Measles
11 Measles
 
Mumps & Rubella.pptx
Mumps & Rubella.pptxMumps & Rubella.pptx
Mumps & Rubella.pptx
 
MEASLES, COMPLICATIONS AND POST DEBILITY.pptx
MEASLES, COMPLICATIONS AND POST DEBILITY.pptxMEASLES, COMPLICATIONS AND POST DEBILITY.pptx
MEASLES, COMPLICATIONS AND POST DEBILITY.pptx
 
Measles
MeaslesMeasles
Measles
 
Common commin child hood
Common commin child hoodCommon commin child hood
Common commin child hood
 
Airborrne and vectorborne
Airborrne and vectorborneAirborrne and vectorborne
Airborrne and vectorborne
 
Measles
MeaslesMeasles
Measles
 
epidemiology of common infectious diseases-resp,git,arthropod.pptx
epidemiology of common infectious diseases-resp,git,arthropod.pptxepidemiology of common infectious diseases-resp,git,arthropod.pptx
epidemiology of common infectious diseases-resp,git,arthropod.pptx
 
Common Pediatric Viral Exanthems
Common Pediatric Viral Exanthems Common Pediatric Viral Exanthems
Common Pediatric Viral Exanthems
 
measles.pdf
measles.pdfmeasles.pdf
measles.pdf
 

More from Liezle Joy Gargoles

Characteristics of benign and malignant neoplasms
Characteristics of benign and malignant neoplasmsCharacteristics of benign and malignant neoplasms
Characteristics of benign and malignant neoplasmsLiezle Joy Gargoles
 

More from Liezle Joy Gargoles (6)

Flowchart
FlowchartFlowchart
Flowchart
 
Clinical practice guidelines
Clinical practice guidelinesClinical practice guidelines
Clinical practice guidelines
 
Poliomyelitis
PoliomyelitisPoliomyelitis
Poliomyelitis
 
Hepatitis B
Hepatitis BHepatitis B
Hepatitis B
 
Potential nursing diagnosis
Potential nursing diagnosisPotential nursing diagnosis
Potential nursing diagnosis
 
Characteristics of benign and malignant neoplasms
Characteristics of benign and malignant neoplasmsCharacteristics of benign and malignant neoplasms
Characteristics of benign and malignant neoplasms
 

Recently uploaded

Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
Little Cross Family Clinic
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
bkling
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
kevinkariuki227
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
NEHA GUPTA
 
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIONDACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
DR SETH JOTHAM
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
Levi Shapiro
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
MedicoseAcademics
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Oleg Kshivets
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
Swetaba Besh
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
Shweta
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
vimalpl1234
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
Sapna Thakur
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
DR SETH JOTHAM
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
KafrELShiekh University
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Savita Shen $i11
 

Recently uploaded (20)

Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
 
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIONDACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
 

Measles

  • 2. Measles or RubeolA, is an acute viral illness caused by a virus in the family paramyxovirus, genus Morbillivirus.
  • 3. Measles is characterized by a prodrome of fever and malaise, cough, coryza, and conjunctivitis, followed by a maculopapular rash.
  • 4. Measles is usually a mild or moderately severe illness. However, measles can result in complications such as pneumonia, encephalitis and death.
  • 5. Epidemiology • In 1980, before widespread global use of measles vaccine, an estimated 2.6 million measles deaths occurred worldwide. In 2001, to accelerate the reduction in measles cases achieved by vaccination, the World Health Organization (WHO) and the United Nations Children's Fund (UNICEF) developed a strategy to deliver 2 doses of measles-containing vaccine (MCV) to all children through routine services and supplementary immunization activities (SIAs) and improved disease surveillance. After implementation of this strategy, the estimated number of annual measles deaths worldwide decreased from 733,000 in 2000 to 164,000 in 2008.
  • 6. Transmission Measles transmission is airborne by respiratory droplet nuclei spread or it can be transmitted by direct contact with infected nasal or throat secretions.
  • 7. Incubation Period The incubation period is approximately ten days, but varies from 7 to 18 days from exposure to the onset of fever. It is usually 14 days until the rash appears.
  • 8. Risk Factors Anyone who never had measles and has never been vaccinated. Babies younger than 12 months old, because they are too young to be vaccinated. Adults who were vaccinated before 1968, because some early vaccines did not give lasting protection. A very small percentage of vaccinated children and adults who may not have responded well to the vaccine.
  • 9. Clinical Features • Clinical features of measles include prodromal fever, a severe cough, conjunctivitis, coryza and Koplik’s spots on the buccal mucosa. These are present for three to four days prior to rash onset.
  • 10. The most important clinical predictors are included in the clinical case definition for measles which is an illness characterised by all the following features:  generalised maculopapular rash, usually lasting three or more days  fever (at least 38°C if measured) present at the time of rash onset  cough, coryza, conjunctivitis and Koplik’s spots  The characteristic red, blotchy rash appears on the third to seventh day. It begins on the face before becoming generalised and generally lasts four to seven days.  Measles infection (confirmed virologically) may rarely occur without a rash.
  • 12. PROBLEM IDENTIFIED STAGE DATA (NURSING DIAGNOSIS) Pre-eruptive Stage • fever • Hyperthermia (patient is highly communicable) • catarrhal symptoms – start in the nasal • Pain cavities; then in the conjunctivae, • Risk for impaired gas exchange oropharynx, progress to the bronchi • Risk for impaired breathing pattern resulting successively in rhinitis, conjunctivitis and then bronchitis. • Respiratory symptoms – which appear first as a common cold, and sneezing nasal discharges, steadily progress into a distressing and annoying cough that persists up to convalescence. Eruptive Stage/Stage of Skin Rashes • Anorexia • Imbalance nutrition: less than body requirement • Exanthem sign – means eruption in the skin • Impaired skin integrity • Maculopapular Rashes – appears 2-7 • Hyperthermia days after onset • Activity Intolerance • High fever – increases steadily • Fatigue • Irritability • Diarrhea • Pruritis • Lethargy • Occipital lymphadenopathy Stage of Convalescence • Rashes – fade in the same manner as they appeared, from the face downwards, leaving a dirty brown pigmentation and finely granular which maybe noted for several days. • Fever – gradually subsides as the eruptions disappear on the hands and feet
  • 13. DIAGNOSIS Clinical diagnosis of measles requires a history of fever of at least three days, with at least one of the three C's (cough, coryza, conjunctivitis). Observation of Koplik's spots is also diagnostic of measles.
  • 14. Alternatively, laboratory diagnosis of measles can be done with confirmation of positive measles IgM antibodies or isolation of measles virus RNA from respiratory specimens. In patients where phlebotomy is not possible, saliva can be collected for salivary measles-specific IgA testing. Positive contact with other patients known to have measles adds strong epidemiological evidence to the diagnosis. The contact with any infected person in any way, including semen through sex, saliva, or mucus, can cause infection.
  • 15. MANAGEMENT • There is no specific treatment for measles. Most patients with uncomplicated measles will recover with rest and supportive treatment. It is, however, important to seek medical advice if the patient becomes more unwell, as they may be developing complications. Patient should be monitored for the development of bacterial infections which should be treated with appropriate antibiotics on the basis of clinical and bacteriological finding • The patient may also take over-the-counter medications such as acetaminophen (Tylenol, others) or nonsteroidal anti-inflammatory drugs (NSAIDs) to help relieve the fever that accompanies measles. Don’t give aspirin to children because of the risk of Reye’s syndrome — a rare but potentially fatal disease. • Maintain bedrest and provide quiet activities for the child. If there is sensitivity to light, keep room darkly lit. Remove eye secretions with warm saline or water. Encourage the patient not to rub the eyes. Administer antipyretic medication and tepid sponge baths as ordered. A cool mist vaporizer can be used to relieve cough. Apply antipruritic medication to prevent itching. Isolate child until fifth day of rash.
  • 16. Prevention of Measles • Avoid exposing children to any person with fever or with acute catarrhal symptoms • Isolation of cases from diagnosis until about 5-7 days after onset of rash • Disinfection of all articles soiled with secretion of nose and throat • Encourage by health department and by private physician of administration of measles immune globulin to susceptible infants and children under 3 years of age in families or institutions where measles occurs. • Live attenuated and inactivated measles virus vaccines have been tested and are available for use in children with no history of measles, at 9 months of age or soon thereafter
  • 17. • Live attenuated measles vaccine is recommended for all persons unless specific contra-indications to live vaccines exist. • It is recommended that this vaccine be given as measles-mumps-rubella (MMR) vaccine at 9 to 12 months of age and a second dose at four years of age (prior to school entry). The second dose is not a booster but is designed to vaccinate the approximately five per cent of children who do not seroconvert to measles after the first dose of vaccine
  • 18. GUIDE ON MEASLES IMMUNIZATION Route Subcutaneous Site Outer part of upper left arm Number of Dose 1 dose Age at First Dose 9 months Dosage 0.5mL Storage Temperature -15 to -25 °C
  • 19. EVALUATION • PROGNOSIS While the vast majority of patients survive measles, complications occur fairly frequently, and may include bronchitis, and panencephalitis which is potentially fatal. Also, even if the patient is not concerned about death or sequela from the measles, the person may spread the disease to an immunocompromised patient, for whom the risk of death is much higher, due to complications such as giant cell pneumonia. Acute measles encephalitis is another serious risk of measles virus infection. It typically occurs two days to one week after the breakout of the measles exanthem, and begins with very high fever, severe headache, convulsions, and altered mentation. Patient may become comatose, and death or brain injury may occur.